Difference between revisions of "Bicalutamide (Casodex)"
Jump to navigation
Jump to search
m |
m (→References) |
||
| Line 29: | Line 29: | ||
[[Category:Drugs FDA approved in 1995]] | [[Category:Drugs FDA approved in 1995]] | ||
| + | [[Category:WHO Essential Cancer Medicine]] | ||
Revision as of 18:53, 5 June 2016
Also known as Cosudex, Calutide, or Kalumid.
General information
Class/mechanism: Antiandrogen; non-steroidal androgen receptor inhibitor that competitively inhibits androgens by binding to cytosol androgen receptors.[1][2]
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, MedscapeUpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
Patient drug information
- Bicalutamide (Casodex) package insert pages 20-24[1]
- Bicalutamide (Casodex) patient drug information (Chemocare)[3]
- Bicalutamide (Casodex) patient drug information (UpToDate)[4]
History of changes in FDA indication
- 10/4/1995: Initial FDA approval
- 5/11/2005: Indicated for use in combination therapy with a luteinizing hormone-releasing hormone (LHRH) analogue for the treatment of Stage D2 metastatic carcinoma of the prostate.